nach oben

Reactions Weekly

Erschienen in:

01.03.2023 | Case report

Insulin degludec/liraglutide

Lack of efficacy and various toxicities: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Auszug

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Abusnana S, et al. Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study. Diabetes Research and Clinical Practice 196: 1-9, Feb 2023. Available from: URL: https://www.elsevier.com/locate/diabres

Titel: Insulin degludec/liraglutide
Lack of efficacy and various toxicities: 4 case reports
Publikationsdatum: 01.03.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-34898-2

Springer Medizin

Insulin degludec/liraglutide

Lack of efficacy and various toxicities: 4 case reports

Auszug

Weitere Artikel der Ausgabe 1/2023

Trimethoprim

Adenosine/amiodarone/lidocaine

Flavins/mycophenolate-mofetil/prednisolone

Durvalumab

Pembrolizumab

AZD-1222

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Trimethoprim

Adenosine/amiodarone/lidocaine

Flavins/mycophenolate-mofetil/prednisolone

Durvalumab

Pembrolizumab

AZD-1222